End-of-day quote
Korea S.E.
23:00:00 25/04/2024 BST
5-day change
1st Jan Change
14,330
KRW
+0.63%
+0.63%
-16.15%
Sales 2022
6.59B
4.77M
381M
Sales 2023
6.5B
4.71M
376M
Capitalization
166B
120M
9.62B
Net income 2022
-6.84B
-4.95M
-396M
Net income 2023
-2.84B
-2.06M
-164M
EV / Sales 2022
15.1
x
Net cash position
2022
43.26B
31.32M
2.5B
Net cash position
2023
40.59B
29.39M
2.35B
EV / Sales 2023
19.3
x P/E ratio 2022
-20.8
x
P/E ratio 2023
-58.5
x
Employees
-
Yield 2022 *
-
Yield 2023
-
Free-Float
77.46%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Anterogen.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
12/05/23
CI
Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment
07/03/21
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment
04/03/21
CI
Anterogen.Co.,Ltd. announced that it has received KRW 12 billion in funding
23/04/20
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 12 billion in funding
22/04/20
CI
An unknown buyer acquired 3.37% stake in Anterogen.Co.,Ltd. for KRW 10 billion.
25/03/20
CI
Anterogen.Co.,Ltd. announced that it has received KRW 4.9999992 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm
06/11/19
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 4.9999992 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm
24/10/19
CI
Anterogen.Co.,Ltd. announced that it has received KRW 13.999979 billion in funding from EM-Tech. CO., LTD.
25/02/19
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 13.999979 billion in funding from EM-Tech. CO., LTD.
14/02/19
CI
Anterogen.Co.,Ltd. announced that it has received KRW 6 billion in funding
31/01/19
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 6 billion in funding
23/01/19
CI
Anterogen.Co.,Ltd. announced that it has received KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm
19/11/18
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, and another investor
07/11/18
CI
Anterogen.Co.,Ltd. announced that it has received KRW 19.99925713 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm
30/10/18
CI
More news
1 day +0.63%
1 week +0.63%
Current month -0.28%
1 month +0.21%
3 months +0.77%
6 months +12.30%
Current year -16.15%
More quotes
Managers
Title Age Since
Chief Executive Officer
55
29/02/04
Chief Executive Officer
69
15/03/00
Chief Tech/Sci/R&D Officer
48
31/08/02
Members of the board
Title Age Since
Chief Executive Officer
69
15/03/00
Chief Executive Officer
55
29/02/04
Director/Board Member
70
28/02/17
More insiders
Date
Price
Change
Volume
26/04/24
14,330
+0.63%
11,558
25/04/24
14,240
-1.32%
18,633
24/04/24
14,430
+0.42%
19,888
23/04/24
14,370
-0.21%
11,951
22/04/24
14,400
+1.12%
22,198
End-of-day quote
Korea S.E., April 25, 2024
More quotes
ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohnâs fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.
More about the company
1st Jan change
Capi.
-16.15% 101M -4.52% 86.13B +1.32% 39.82B -19.27% 30.42B +57.86% 25.23B -16.09% 15.36B -9.14% 11.95B -17.69% 11.6B -43.00% 11.51B +5.24% 8.71B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1